Related Experiment Videos
[Budd-Chiari syndrome: updated treatment modalities].
1Department of Internal Medicine A, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Harefuah
|June 12, 2004
Summary
Budd-Chiari Syndrome (BCS) involves hepatic venous outflow obstruction. Treatment for BCS ranges from conservative anticoagulation to invasive procedures like shunting or liver transplantation, depending on disease severity and hepatic damage.
Area of Science:
- Hepatology
- Vascular Medicine
- Interventional Radiology
Context:
- Budd-Chiari Syndrome (BCS) is characterized by hepatic venous outflow obstruction.
- Western BCS cases are often linked to hypercoagulable states, unlike Asian/African cases primarily caused by membranous webs.
- Clinical presentation includes right upper quadrant pain, hepatomegaly, and ascites.
Purpose:
- To outline the diagnostic and therapeutic strategies for Budd-Chiari Syndrome.
- To differentiate treatment approaches based on the presence and severity of hepatic damage.
- To highlight the role of anticoagulation and invasive interventions in managing BCS.
Summary:
- BCS management involves a tiered approach: conservative therapy (diuretics, anticoagulants) for early stages without significant liver damage.
- For progressive disease or irreversible hepatic damage, invasive treatments are necessary, including surgical shunting, TransJugular Intrahepatic Porto-Systemic Shunt (TIPS), angioplasty with stenting, or liver transplantation.
- Treatment selection depends on the extent of hepatic insult and the anatomical nature of the venous obstruction.
Impact:
- Early recognition of hypercoagulability is crucial for initiating anticoagulation therapy.
- Timely and appropriate interventions can prevent disease progression and improve patient outcomes.
- Liver transplantation offers excellent results for advanced BCS with significant hepatic damage.